Drugs / BCD-264
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05974969 | May → Aug 2023 | — | Biocad | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06296121 | Dec 2023 → Jan 2025 overdue | plasma cell myeloma | Biocad | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCD-264 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06296121 ↗ |
| Route | Intravenous | “single intravenous infusion of BCD-264” NCT05974969 ↗ |